- Home
- UAL vs ARGX Comparison
UAL vs ARGX Comparison
Compare UAL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- ARGX
- Stock Information
- Founded
- UAL 1934
- ARGX 2008
- Country
- UAL United States
- ARGX Netherlands
- Employees
- UAL N/A
- ARGX N/A
- Industry
- UAL Air Freight/Delivery Services
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAL Consumer Discretionary
- ARGX Health Care
- Exchange
- UAL Nasdaq
- ARGX Nasdaq
- Market Cap
- UAL 31.6B
- ARGX 37.3B
- IPO Year
- UAL N/A
- ARGX 2017
- Fundamental
- Price
- UAL $107.38
- ARGX $640.52
- Analyst Decision
- UAL Strong Buy
- ARGX Strong Buy
- Analyst Count
- UAL 17
- ARGX 20
- Target Price
- UAL $102.95
- ARGX $653.11
- AVG Volume (30 Days)
- UAL 5.2M
- ARGX 236.4K
- Earning Date
- UAL 01-21-2025
- ARGX 02-27-2025
- Dividend Yield
- UAL N/A
- ARGX N/A
- EPS Growth
- UAL N/A
- ARGX N/A
- EPS
- UAL 8.30
- ARGX N/A
- Revenue
- UAL $55,994,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- UAL $6.58
- ARGX $70.98
- Revenue Next Year
- UAL $6.87
- ARGX $51.22
- P/E Ratio
- UAL $12.94
- ARGX N/A
- Revenue Growth
- UAL 6.67
- ARGX 85.56
- 52 Week Low
- UAL $37.02
- ARGX $349.86
- 52 Week High
- UAL $110.92
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- UAL 64.42
- ARGX 52.90
- Support Level
- UAL $104.38
- ARGX $657.10
- Resistance Level
- UAL $110.15
- ARGX $678.21
- Average True Range (ATR)
- UAL 3.50
- ARGX 15.00
- MACD
- UAL 0.46
- ARGX 0.45
- Stochastic Oscillator
- UAL 81.50
- ARGX 42.20
About UAL United Airlines Holdings Inc.
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.